open access

Vol 63, No 4 (2004)
ORIGINAL ARTICLES
Published online: 2004-09-16
Submitted: 2012-02-06
Get Citation

The influence of chemotherapy on bone marrow in patients with chronic lymphocytic leukaemia

Dorota Lemancewicz, Janusz Dzięcioł, Janusz Kłoczko, Jarosław Piszcz
Folia Morphol 2004;63(4):485-489.

open access

Vol 63, No 4 (2004)
ORIGINAL ARTICLES
Published online: 2004-09-16
Submitted: 2012-02-06

Abstract

In chronic lymphocytic leukaemia (CLL) bone marrow trephine biopsy (BMT) is not required for diagnosis but can have a significant prognostic value and can be used for the detection of the minimal residual disease (MRD) and for assessment of the effectiveness of the treatment applied. The aim of the study was to evaluate the morphological changes in bone marrow after treatment with purine nucleoside analogues cladribine and fludarabine. Bone marrow trephine biopsy was taken routinely from 15 patients with CLL. Bone marrow trephine biopsy was performed on every patient before as well as after chemotherapy. The number of cell elements of the marrow (the degree of atrophy), the patterns of bone marrow infiltration, the presence of reticulin and collagen fibres and the disturbances in bone marrow stroma were assessed. The infiltration of bone marrow by neoplastic cells was observed in all the patients before administration of chemotherapy. The infiltration was followed by an increase in the number of reticulin fibres. After the treatment a regression of the reticulin fibres was observed with the lessening of the infiltration. After the treatment the levels of marrow infiltrate were decreased. Increased hypoplasia of the bone marrow was observed after the chemotherapy.

Abstract

In chronic lymphocytic leukaemia (CLL) bone marrow trephine biopsy (BMT) is not required for diagnosis but can have a significant prognostic value and can be used for the detection of the minimal residual disease (MRD) and for assessment of the effectiveness of the treatment applied. The aim of the study was to evaluate the morphological changes in bone marrow after treatment with purine nucleoside analogues cladribine and fludarabine. Bone marrow trephine biopsy was taken routinely from 15 patients with CLL. Bone marrow trephine biopsy was performed on every patient before as well as after chemotherapy. The number of cell elements of the marrow (the degree of atrophy), the patterns of bone marrow infiltration, the presence of reticulin and collagen fibres and the disturbances in bone marrow stroma were assessed. The infiltration of bone marrow by neoplastic cells was observed in all the patients before administration of chemotherapy. The infiltration was followed by an increase in the number of reticulin fibres. After the treatment a regression of the reticulin fibres was observed with the lessening of the infiltration. After the treatment the levels of marrow infiltrate were decreased. Increased hypoplasia of the bone marrow was observed after the chemotherapy.
Get Citation

Keywords

bone marrow trephine biopsy; lymphoid infiltration; reticulin fibrosis

About this article
Title

The influence of chemotherapy on bone marrow in patients with chronic lymphocytic leukaemia

Journal

Folia Morphologica

Issue

Vol 63, No 4 (2004)

Pages

485-489

Published online

2004-09-16

Bibliographic record

Folia Morphol 2004;63(4):485-489.

Keywords

bone marrow trephine biopsy
lymphoid infiltration
reticulin fibrosis

Authors

Dorota Lemancewicz
Janusz Dzięcioł
Janusz Kłoczko
Jarosław Piszcz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By  "Via Medica sp. z o.o." sp.k., Świętokrzyska 73, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl